UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 139

Sortiert nach

C5a Receptor (CD88) Blockade Protects against MPO-ANCA GN

Journal of the American Society of Nephrology, 2014-02, Vol.25 (2), p.225-231

2014

Link zum Volltext

Verfügbarkeit prüfen

Characterization of Pharmacologic and Pharmacokinetic Properties of CCX168, a Potent and Selective Orally Administered Complement 5a Receptor Inhibitor, Based on Preclinical Evaluation and Randomized Phase 1 Clinical Study

PloS one, 2016-10, Vol.11 (10), p.e0164646-e0164646

2016

Link zum Volltext

Verfügbarkeit prüfen

Novel effective small-molecule inhibitors of protein kinases related to tau pathology in Alzheimer's disease

Future medicinal chemistry, 2022-08, Vol.14 (16), p.1175-1186

2022

Link zum Volltext

Verfügbarkeit prüfen

CCR1 blockade reduces tumor burden and osteolysis in vivo in a mouse model of myeloma bone disease

Blood, 2012-08, Vol.120 (7), p.1449-1457

2012

Link zum Volltext

Verfügbarkeit prüfen

Safety, tolerability, and pharmacology of AB928, a novel dual adenosine receptor antagonist, in a randomized, phase 1 study in healthy volunteers

Investigational new drugs, 2019-08, Vol.37 (4), p.711-721

2019

Link zum Volltext

Verfügbarkeit prüfen

Experimental evidence for the use of CCR2 antagonists in the treatment of type 2 diabetes

Metabolism, clinical and experimental, 2013-11, Vol.62 (11), p.1623-1632

2013

Link zum Volltext

Verfügbarkeit prüfen

CCR2 antagonist CCX140-B provides renal and glycemic benefits in diabetic transgenic human CCR2 knockin mice

American journal of physiology. Renal physiology, 2013-11, Vol.305 (9), p.F1288-F1297

2013

Link zum Volltext

Verfügbarkeit prüfen

475 Fc-silent anti-TIGIT antibodies potentiate anti-tumor immunity without depleting regulatory T cells

Journal for immunotherapy of cancer, 2023-11, Vol.11 (Suppl 1), p.A534-A534

2023

Link zum Volltext

Verfügbarkeit prüfen

338 Emerging insights on the association of tumor molecular phenotype with clinical benefit in metastatic colorectal cancer (mCRC) subjects treated with AB928 + modified FOLFOX-6 (mFOLFOX-6)

Journal for immunotherapy of cancer, 2020-11, Vol.8 (Suppl 3), p.A206-A207

2020

Link zum Volltext

Verfügbarkeit prüfen

Discovery of AMG 853, a CRTH2 and DP Dual Antagonist

ACS medicinal chemistry letters, 2011-05, Vol.2 (5), p.326-330

2011

Link zum Volltext

Verfügbarkeit prüfen

Synthesis and Evaluation of Novel Substituted N-Aryl 1,4-Dihydropyridines as Antituberculostatic Agents

Medicinal chemistry (Shp-sariqah, United Arab Emirates), 2024, Vol.20 (1), p.30

2024

Link zum Volltext

Verfügbarkeit prüfen

Abstract 4100: Receptor occupancy and neo-epitope specific T-cell repertoires in patients with solid tissue tumors following anti-PD-1 therapy

Cancer research (Chicago, Ill.), 2019-07, Vol.79 (13_Supplement), p.4100-4100

2019

Link zum Volltext

Verfügbarkeit prüfen

Anti-TIGIT antibodies promote immune activation relevant to targeting stem-like and tumor-specific T cells in combination with anti-PD-1

The Journal of immunology (1950), 2022-05, Vol.208 (1_Supplement), p.120-120.13

2022

Link zum Volltext

Verfügbarkeit prüfen

Abstract 1557: Characterization of AB154, a humanized anti-TIGIT antibody, for use in combination studies

Cancer research (Chicago, Ill.), 2019-07, Vol.79 (13_Supplement), p.1557-1557

2019

Link zum Volltext

Verfügbarkeit prüfen

Abstract LB-387: Efficacy and safety of AB928 plus modified FOLFOX-6 (mFOLFOX-6) in participants with metastatic colorectal cancer (mCRC): Initial results at the recommended dose for expansion (ARC-3)

Cancer research (Chicago, Ill.), 2020-08, Vol.80 (16_Supplement), p.LB-387-LB-387

2020

Link zum Volltext

Verfügbarkeit prüfen

AB928, a novel dual adenosine receptor antagonist, combined with chemotherapy or AB122 (anti-PD-1) in patients (pts) with advanced tumors: Preliminary results from ongoing phase I studies

Journal of clinical oncology, 2019-05, Vol.37 (15_suppl), p.2604-2604

2019

Link zum Volltext

Verfügbarkeit prüfen

Real life treatment of diabetes mellitus type 2 patients: An analysis based on a large sample of 394,828 German patients

Diabetes research and clinical practice, 2014-11, Vol.106 (2), p.275-285

2014

Link zum Volltext

Verfügbarkeit prüfen

Abstract 3168: Methods for assessment of the “adenosine fingerprint” in clinical trials of AB928

Cancer research (Chicago, Ill.), 2019-07, Vol.79 (13_Supplement), p.3168-3168

2019

Link zum Volltext

Verfügbarkeit prüfen

The rad9 gene of Coprinus cinereus encodes a proline-rich protein required for meiotic chromosome condensation and synapsis

Genetics (Austin), 1996-04, Vol.142 (4), p.1105-1117

1996

Link zum Volltext

Verfügbarkeit prüfen

Abstract 3769: Pharmacokinetic-pharmacodynamic relationship for AB928, a dual antagonist of the A2aR and A2bR adenosine receptors

Cancer research (Chicago, Ill.), 2018-07, Vol.78 (13_Supplement), p.3769-3769

2018

Link zum Volltext

Verfügbarkeit prüfen

Abstract 4600: Potent and selective C-C chemokine receptor (CCR4) antagonists potentiate anti-tumor immune responses by inhibiting regulatory T cells (Treg)

Cancer research (Chicago, Ill.), 2017-07, Vol.77 (13_Supplement), p.4600-4600

2017

Link zum Volltext

Verfügbarkeit prüfen

Genetic analysis of mecillinam-resistant mutants of Caulobacter crescentus deficient in stalk biosynthesis

Journal of bacteriology, 1998-10, Vol.180 (19), p.5235-5239

1998

Link zum Volltext

Verfügbarkeit prüfen

An analysis of product wastage arising from dosing increment granularity in four modern growth hormone administration devices

Expert opinion on drug delivery, 2015-03, Vol.12 (3), p.353-360

2015

Link zum Volltext

Verfügbarkeit prüfen

Treatment-dependent and treatment-independent risk factors associated with the risk of diabetes-related events: a retrospective analysis based on 229,042 patients with type 2 diabetes mellitus

Cardiovascular diabetology, 2015-02, Vol.14 (1), p.14-14

2015

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 139

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(125)
Mit Volltextzugriff
(123)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

C5a Receptor (CD88) Blockade Protects against MPO-ANCA GN

Characterization of Pharmacologic and Pharmacokinetic Properties of CCX168, a Potent and Selective Orally Administered Complement 5a Receptor Inhibitor, Based on Preclinical Evaluation and Randomized Phase 1 Clinical Study

Novel effective small-molecule inhibitors of protein kinases related to tau pathology in Alzheimer's disease

CCR1 blockade reduces tumor burden and osteolysis in vivo in a mouse model of myeloma bone disease

Safety, tolerability, and pharmacology of AB928, a novel dual adenosine receptor antagonist, in a randomized, phase 1 study in healthy volunteers

Experimental evidence for the use of CCR2 antagonists in the treatment of type 2 diabetes

CCR2 antagonist CCX140-B provides renal and glycemic benefits in diabetic transgenic human CCR2 knockin mice

Correction: Characterization of Pharmacologic and Pharmacokinetic Properties of CCX168, a Potent and Selective Orally Administered Complement 5a Receptor Inhibitor, Based on Preclinical Evaluation and Randomized Phase 1 Clinical Study

475 Fc-silent anti-TIGIT antibodies potentiate anti-tumor immunity without depleting regulatory T cells

338 Emerging insights on the association of tumor molecular phenotype with clinical benefit in metastatic colorectal cancer (mCRC) subjects treated with AB928 + modified FOLFOX-6 (mFOLFOX-6)

Discovery of AMG 853, a CRTH2 and DP Dual Antagonist

Synthesis and Evaluation of Novel Substituted N-Aryl 1,4-Dihydropyridines as Antituberculostatic Agents

Abstract 4100: Receptor occupancy and neo-epitope specific T-cell repertoires in patients with solid tissue tumors following anti-PD-1 therapy

Anti-TIGIT antibodies promote immune activation relevant to targeting stem-like and tumor-specific T cells in combination with anti-PD-1

Abstract 1557: Characterization of AB154, a humanized anti-TIGIT antibody, for use in combination studies

Abstract LB-387: Efficacy and safety of AB928 plus modified FOLFOX-6 (mFOLFOX-6) in participants with metastatic colorectal cancer (mCRC): Initial results at the recommended dose for expansion (ARC-3)

AB928, a novel dual adenosine receptor antagonist, combined with chemotherapy or AB122 (anti-PD-1) in patients (pts) with advanced tumors: Preliminary results from ongoing phase I studies

Real life treatment of diabetes mellitus type 2 patients: An analysis based on a large sample of 394,828 German patients

Abstract 3168: Methods for assessment of the “adenosine fingerprint” in clinical trials of AB928

The rad9 gene of Coprinus cinereus encodes a proline-rich protein required for meiotic chromosome condensation and synapsis

Abstract 3769: Pharmacokinetic-pharmacodynamic relationship for AB928, a dual antagonist of the A2aR and A2bR adenosine receptors

Abstract 4600: Potent and selective C-C chemokine receptor (CCR4) antagonists potentiate anti-tumor immune responses by inhibiting regulatory T cells (Treg)

Genetic analysis of mecillinam-resistant mutants of Caulobacter crescentus deficient in stalk biosynthesis

An analysis of product wastage arising from dosing increment granularity in four modern growth hormone administration devices

Treatment-dependent and treatment-independent risk factors associated with the risk of diabetes-related events: a retrospective analysis based on 229,042 patients with type 2 diabetes mellitus

Suchergebnisse filtern